MARKET WIRECNBC • 2h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why IMCR Stock dropped -4.11% Today — RQD Quant Desk Flash
$31.27 -4.11% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $30.98
Immunocore Holdings plc (IMCR) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $1.61B
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $30.98 (-0.93%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-12.2% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IMCR)Realized 20D OHLCV Swing Band: ±9.2%
Deterministic 5-Pillar Attribution (31/100 Composite)
🔍 WHY IMCR SCORES 31/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+10/20 pts (32% of score)
FRED Regime × Technicals: 29% of 52W Range • RSI-14 at 46.4 (NEUTRAL RANGE)
▲ #2 Bullish Driver: Whale & Options Positioning+8/20 pts (26% of score)
20D Institutional Volume Accumulation (±9.2% realized swing band)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$29.39+0% Next Q
23
Q2 (-2Q)Grade E$29.40+5.4% Next Q
26
Q3 (-1Q)Grade E$30.98+0.9% Next Q
28
CurrentGrade E$31.27-9.4% Hist 90D α
31
Trajectory: E (23) → E (31)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a IMCR Turnaround Squeeze
While IMCR currently carries a cautious 31/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($32.37) and Max Pain ($32.83) forces dealer call-delta covering toward $42.76.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $IMCR• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “IMCR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why IMCR Stock dropped -4.11% Today — RQD Quant Desk Flash
Immunocore Holdings plc (IMCR) dropped -4.11% to $31.27, trading at 29% of its 52-week range ($27.5 – $40.72). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 29% of its 52-week range ($27.5 – $40.72) with RSI-14 at 46.4 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±9.2% around $31.27 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 98.7% gross margin and $0 annual free cash flow.
Live IMCR Headlines & Catalysts
MARKET WIRECNBC • 3h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 4h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 5h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 6h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 7h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 7h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 7h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring IMCR)
- ✓Walkthrough of IMCR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
IMCR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +12.04%📐 HORIZONTAL RANGE
2026-10-30O $31.00H $31.44L $30.13C $31.27VOL 290.2K
RES: $40.26SUP: $26.41SMA50: $32.37SMA200: $31.76
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
IMCR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +29.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on IMCR today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for IMCR. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for IMCR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IMCR)
Health Care Rank #908 of 1016
⚔️ REPL vs IMCR Full Matrix →
1. Head-to-Head Health Care Peer Comparison (IMCR vs. REPL, NVAX, MAZE, LYCA)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Immunocore Holdings plc (IMCR) ranks #908 by composite RQD confidence (31/100, grade E) and #297 by equity capitalization ($1.61B). Within this direct 5-issuer industry benchmark cohort, NVAX leads on earnings valuation at 3.9x trailing P/E, while NVAX leads on capital efficiency and profitability with 85.0% ROIC and 93.5% gross margin. LYCA currently holds the highest overall quantitative score in the immediate peer group at 59/100 (C-) compared with IMCR at 31/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| IMCR
ACTIVE
Immunocore Holdings plc | E | 31/100 | — | 96.0% | -35.0% | -4.11% | $1.61B | Benchmark Subject |
| REPL Replimune Group Inc. | D | 46/100 | — | — | -35.0% | +8.28% | $1.65B | /repl-vs-imcr → |
| NVAX Novavax Inc. | D+ | 56/100 | 3.9x | 93.5% | 85.0% | +1.45% | $1.73B | /nvax-vs-imcr → |
| MAZE Maze Therapeutics Inc. | D | 45/100 | — | — | -35.0% | +0.63% | $1.77B | /maze-vs-imcr → |
| LYCA Lycia Therapeutics Inc. | C- | 59/100 | — | — | — | +10.70% | $1.44B | /lyca-vs-imcr → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001671927In its most recent audited fiscal period (FY2025, filed 2025-12-31), Immunocore Holdings plc (IMCR) reported GAAP revenue of $400.0M (+29.0% vs. FY2024 revenue of $310.2M , and +60.4% cumulative change since FY2023) , GAAP net income of -$35.5M, operating cash flow of -$10.7M, and free cash flow of -$15.1M (-172.1% YoY). On the balance sheet, IMCR closed FY2025 with $1.07B in total assets against $0 in total debt (Altman Z-Score: 1.40, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $400.0M | -$35.5M | -$10.7M | -$15.1M | $1.07B | — |
| FY2024 (FY) | 2024-12-31 | $310.2M | -$51.1M | $26.1M | $20.9M | $1.01B | — |
| FY2023 (FY) | 2023-12-31 | $249.4M | -$55.3M | $2.9M | $2.9M | — | — |
3. IMCR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs IMCR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Immunocore Holdings plc (NASDAQ: IMCR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $31.27 (-4.11% 1D, market cap $1.61B). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, IMCR ranks #908 in composite RQD confidence.
How does IMCR compare to REPL and NVAX in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), IMCR carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of -35.0%. By comparison, REPL (Replimune Group Inc.) holds a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $1.65B) and NVAX (Novavax Inc.) posts a D+ grade (56/100 RQD, P/E 3.9x, ROIC 85.0%, cap $1.73B). Among the 5-stock peer group, NVAX leads on earnings multiple (3.9x) while NVAX leads on capital efficiency (85.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for IMCR?
Per IMCR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001671927), Immunocore Holdings plc generated $400.0M in revenue (+29.0% YoY), -$35.5M in net income, and -$15.1M in free cash flow against $1.07B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is IMCR trading relative to its 50-day, 200-day, and 52-week technical levels?
IMCR last traded at $31.27 (-4.11% on volume of 1,287,159 shares), positioning the stock -3.40% below its 50-day simple moving average ($32.37) and -1.54% below its 200-day simple moving average ($31.76). Across its 52-week range of $27.50 to $40.72, IMCR sits at the 28.5% percentile with a 14-day RSI of 46.4 (NEUTRAL RANGE) and an implied next-earnings move of ±9.2% ($28.39 to $34.15).
IMCR Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is IMCR stock moving today?
Why IMCR Stock dropped -4.11% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.